世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

胃癌治療薬の世界市場レポート、歴史と予測2018-2029年、企業別、主要地域別、タイプ別、用途別内訳データ


Global Gastric Carcinomas Drugs Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

胃癌は胃粘膜の癌である。初期症状として、胸やけ、上腹部痛、吐き気、食欲不振などがある。症状は消化性潰瘍と類似しているため、治療が遅れ、死亡率が高い。 QYResearch発行の胃癌治療薬に関する調査レポート... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2023年10月23日 US$3,350
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

胃癌は胃粘膜の癌である。初期症状として、胸やけ、上腹部痛、吐き気、食欲不振などがある。症状は消化性潰瘍と類似しているため、治療が遅れ、死亡率が高い。
QYResearch発行の胃癌治療薬に関する調査レポートは、2022年にCOVID-19とロシア・ウクライナ戦争が市場に影響を与えることを明らかにしている。胃癌治療薬の世界市場は、2023年から2029年の間に年平均成長率%で、2022年の100万米ドルから増加し、2029年には100万米ドルに達すると予測されています。病院と診療所からの需要が業界の主要な推進力である。

世界の医薬品市場は、2022年には1,475億米ドルとなり、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的医薬品が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

レポートの範囲
本レポートは、過去の分析(2018-2022年)と予測計算(2023-2029年)に基づき、読者が世界の胃癌治療薬市場を多角的に包括的に理解することを目的とし、読者の戦略と意思決定に十分なサポートを提供します。

本レポートに掲載されている企業、タイプ、用途、地域
企業別
ファイザー
ノボノルディスク
バイエル
メルク社
ロシュ
イーライリリー・アンド・カンパニー
大鵬薬品工業
江蘇恒瑞医薬有限公司
福建海王福耀薬業有限公司
斉魯薬業
山東新時代ホテル医薬工業有限公司
嘉泰天青
タイプ別セグメント
ファーストライン治療
セカンドライン治療
スリーライン治療
用途別セグメント
病院
クリニック
その他
地域別
北米
アメリカ
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
北欧諸国

アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア

ラテンアメリカ
メキシコ
ブラジル

中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

本レポートの各章は、読者が胃癌治療薬市場をさらに理解するための詳細情報を提供しています:
第1章:歴史と予測期間(2018-2023年、2024-2029年)における世界と地域の市場規模とCAGR。
第2章:2018年から2023年までの北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカにおける各タイプの製品タイプと収益分析。
第3章:2018年から2023年までの北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカにおける製品用途と各用途の収益分析。
第4章:企業競争状況、製品名企業の競争状況、収益、市場シェアとランキング、最新の開発計画、合併、買収情報などの詳細分析。
第5章:企業概要:企業の基本情報、胃がん治療薬の紹介などをカバーする。各企業の胃がん治療薬の売上高と売上総利益率、最近の開発状況もこの部分に含まれています。
第6章から第10章:北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカの国別レベル分析(収益別)。
第11章:市場力学、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク。
第12章:包括的調査に基づく胃癌治療薬市場に関するQYResearch社の結論
第13章:QYResearchが採用した方法論とデータソース。


ページTOPに戻る


目次

1 Market Overview of Gastric Carcinomas Drugs
1.1 Gastric Carcinomas Drugs Market Overview
1.1.1 Gastric Carcinomas Drugs Product Scope
1.1.2 Gastric Carcinomas Drugs Market Status and Outlook
1.2 Global Gastric Carcinomas Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gastric Carcinomas Drugs Market Size by Region (2018-2029)
1.4 Global Gastric Carcinomas Drugs Historic Market Size by Region (2018-2023)
1.5 Global Gastric Carcinomas Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.1 North America Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.2 Europe Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.4 Latin America Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Gastric Carcinomas Drugs Market Size (2018-2029)
2 Gastric Carcinomas Drugs Market by Type
2.1 Introduction
2.1.1 First Line Treatment
2.1.2 Second Line Treatment
2.1.3 Three Line Treatment
2.2 Global Gastric Carcinomas Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
3 Gastric Carcinomas Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Gastric Carcinomas Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
4 Gastric Carcinomas Drugs Competition Analysis by Players
4.1 Global Gastric Carcinomas Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2022)
4.3 Date of Key Players Enter into Gastric Carcinomas Drugs Market
4.4 Global Top Players Gastric Carcinomas Drugs Headquarters and Area Served
4.5 Key Players Gastric Carcinomas Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Gastric Carcinomas Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Gastric Carcinomas Drugs Products, Services and Solutions
5.1.4 Pfizer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novo Nordisk
5.2.1 Novo Nordisk Profile
5.2.2 Novo Nordisk Main Business
5.2.3 Novo Nordisk Gastric Carcinomas Drugs Products, Services and Solutions
5.2.4 Novo Nordisk Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Novo Nordisk Recent Developments
5.3 Bayer
5.3.1 Bayer Profile
5.3.2 Bayer Main Business
5.3.3 Bayer Gastric Carcinomas Drugs Products, Services and Solutions
5.3.4 Bayer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Merck & Co Recent Developments
5.4 Merck & Co
5.4.1 Merck & Co Profile
5.4.2 Merck & Co Main Business
5.4.3 Merck & Co Gastric Carcinomas Drugs Products, Services and Solutions
5.4.4 Merck & Co Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Merck & Co Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Gastric Carcinomas Drugs Products, Services and Solutions
5.5.4 Roche Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 Eli Lilly and Company
5.6.1 Eli Lilly and Company Profile
5.6.2 Eli Lilly and Company Main Business
5.6.3 Eli Lilly and Company Gastric Carcinomas Drugs Products, Services and Solutions
5.6.4 Eli Lilly and Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Eli Lilly and Company Recent Developments
5.7 Taiho Pharmaceutical
5.7.1 Taiho Pharmaceutical Profile
5.7.2 Taiho Pharmaceutical Main Business
5.7.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Products, Services and Solutions
5.7.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Taiho Pharmaceutical Recent Developments
5.8 Jiangsu Hengrui Medicine Company Limited
5.8.1 Jiangsu Hengrui Medicine Company Limited Profile
5.8.2 Jiangsu Hengrui Medicine Company Limited Main Business
5.8.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Products, Services and Solutions
5.8.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Jiangsu Hengrui Medicine Company Limited Recent Developments
5.9 Fujian Haiwang Fuyao Pharmacy Limited Company
5.9.1 Fujian Haiwang Fuyao Pharmacy Limited Company Profile
5.9.2 Fujian Haiwang Fuyao Pharmacy Limited Company Main Business
5.9.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Products, Services and Solutions
5.9.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments
5.10 Qilu Pharma
5.10.1 Qilu Pharma Profile
5.10.2 Qilu Pharma Main Business
5.10.3 Qilu Pharma Gastric Carcinomas Drugs Products, Services and Solutions
5.10.4 Qilu Pharma Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Qilu Pharma Recent Developments
5.11 Shandong New Era Hotel Pharmaceutical Industry Limited Company
5.11.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Profile
5.11.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Main Business
5.11.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Products, Services and Solutions
5.11.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments
5.12 Chiatai Tianqing
5.12.1 Chiatai Tianqing Profile
5.12.2 Chiatai Tianqing Main Business
5.12.3 Chiatai Tianqing Gastric Carcinomas Drugs Products, Services and Solutions
5.12.4 Chiatai Tianqing Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Chiatai Tianqing Recent Developments
6 North America
6.1 North America Gastric Carcinomas Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Gastric Carcinomas Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gastric Carcinomas Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gastric Carcinomas Drugs Market Dynamics
11.1 Gastric Carcinomas Drugs Industry Trends
11.2 Gastric Carcinomas Drugs Market Drivers
11.3 Gastric Carcinomas Drugs Market Challenges
11.4 Gastric Carcinomas Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

 

ページTOPに戻る


 

Summary

Gastric Carcinomas is a cancer of the gastric mucosa. Early symptoms include heartburn, upper abdominal pain, nausea, and loss of appetite. Symptoms are similar to those of peptic ulcers, leading to delayed treatment and a high mortality rate.
Gastric Carcinomas Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gastric Carcinomas Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Demand from Hospital and Clinic are the major drivers for the industry.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gastric Carcinomas Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Companies, Type, Application and Regions Listed in the Report:
By Company
Pfizer
Novo Nordisk
Bayer
Merck & Co
Roche
Eli Lilly and Company
Taiho Pharmaceutical
Jiangsu Hengrui Medicine Company Limited
Fujian Haiwang Fuyao Pharmacy Limited Company
Qilu Pharma
Shandong New Era Hotel Pharmaceutical Industry Limited Company
Chiatai Tianqing
Segment by Type
First Line Treatment
Second Line Treatment
Three Line Treatment
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE

Each chapter of the report provides detailed information for readers to understand the Gastric Carcinomas Drugs market further:
Chapter 1: Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029).
Chapter 2: Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3: Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4: Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Companies’ Outline, covering company’s basic information, Gastric Carcinomas Drugs introduction, etc. Gastric Carcinomas Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10: Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11: Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12: QYResearch’s Conclusions of Gastric Carcinomas Drugs market based on comprehensive survey.
Chapter 13: Methodology and Data Sources adopted by QYResearch.



ページTOPに戻る


Table of Contents

1 Market Overview of Gastric Carcinomas Drugs
1.1 Gastric Carcinomas Drugs Market Overview
1.1.1 Gastric Carcinomas Drugs Product Scope
1.1.2 Gastric Carcinomas Drugs Market Status and Outlook
1.2 Global Gastric Carcinomas Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gastric Carcinomas Drugs Market Size by Region (2018-2029)
1.4 Global Gastric Carcinomas Drugs Historic Market Size by Region (2018-2023)
1.5 Global Gastric Carcinomas Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.1 North America Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.2 Europe Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.4 Latin America Gastric Carcinomas Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Gastric Carcinomas Drugs Market Size (2018-2029)
2 Gastric Carcinomas Drugs Market by Type
2.1 Introduction
2.1.1 First Line Treatment
2.1.2 Second Line Treatment
2.1.3 Three Line Treatment
2.2 Global Gastric Carcinomas Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Type (2018-2029)
3 Gastric Carcinomas Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Gastric Carcinomas Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gastric Carcinomas Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gastric Carcinomas Drugs Revenue Breakdown by Application (2018-2029)
4 Gastric Carcinomas Drugs Competition Analysis by Players
4.1 Global Gastric Carcinomas Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2022)
4.3 Date of Key Players Enter into Gastric Carcinomas Drugs Market
4.4 Global Top Players Gastric Carcinomas Drugs Headquarters and Area Served
4.5 Key Players Gastric Carcinomas Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Gastric Carcinomas Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Gastric Carcinomas Drugs Products, Services and Solutions
5.1.4 Pfizer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novo Nordisk
5.2.1 Novo Nordisk Profile
5.2.2 Novo Nordisk Main Business
5.2.3 Novo Nordisk Gastric Carcinomas Drugs Products, Services and Solutions
5.2.4 Novo Nordisk Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Novo Nordisk Recent Developments
5.3 Bayer
5.3.1 Bayer Profile
5.3.2 Bayer Main Business
5.3.3 Bayer Gastric Carcinomas Drugs Products, Services and Solutions
5.3.4 Bayer Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Merck & Co Recent Developments
5.4 Merck & Co
5.4.1 Merck & Co Profile
5.4.2 Merck & Co Main Business
5.4.3 Merck & Co Gastric Carcinomas Drugs Products, Services and Solutions
5.4.4 Merck & Co Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Merck & Co Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Gastric Carcinomas Drugs Products, Services and Solutions
5.5.4 Roche Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 Eli Lilly and Company
5.6.1 Eli Lilly and Company Profile
5.6.2 Eli Lilly and Company Main Business
5.6.3 Eli Lilly and Company Gastric Carcinomas Drugs Products, Services and Solutions
5.6.4 Eli Lilly and Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Eli Lilly and Company Recent Developments
5.7 Taiho Pharmaceutical
5.7.1 Taiho Pharmaceutical Profile
5.7.2 Taiho Pharmaceutical Main Business
5.7.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Products, Services and Solutions
5.7.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Taiho Pharmaceutical Recent Developments
5.8 Jiangsu Hengrui Medicine Company Limited
5.8.1 Jiangsu Hengrui Medicine Company Limited Profile
5.8.2 Jiangsu Hengrui Medicine Company Limited Main Business
5.8.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Products, Services and Solutions
5.8.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Jiangsu Hengrui Medicine Company Limited Recent Developments
5.9 Fujian Haiwang Fuyao Pharmacy Limited Company
5.9.1 Fujian Haiwang Fuyao Pharmacy Limited Company Profile
5.9.2 Fujian Haiwang Fuyao Pharmacy Limited Company Main Business
5.9.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Products, Services and Solutions
5.9.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments
5.10 Qilu Pharma
5.10.1 Qilu Pharma Profile
5.10.2 Qilu Pharma Main Business
5.10.3 Qilu Pharma Gastric Carcinomas Drugs Products, Services and Solutions
5.10.4 Qilu Pharma Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Qilu Pharma Recent Developments
5.11 Shandong New Era Hotel Pharmaceutical Industry Limited Company
5.11.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Profile
5.11.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Main Business
5.11.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Products, Services and Solutions
5.11.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments
5.12 Chiatai Tianqing
5.12.1 Chiatai Tianqing Profile
5.12.2 Chiatai Tianqing Main Business
5.12.3 Chiatai Tianqing Gastric Carcinomas Drugs Products, Services and Solutions
5.12.4 Chiatai Tianqing Gastric Carcinomas Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Chiatai Tianqing Recent Developments
6 North America
6.1 North America Gastric Carcinomas Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Gastric Carcinomas Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gastric Carcinomas Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gastric Carcinomas Drugs Market Dynamics
11.1 Gastric Carcinomas Drugs Industry Trends
11.2 Gastric Carcinomas Drugs Market Drivers
11.3 Gastric Carcinomas Drugs Market Challenges
11.4 Gastric Carcinomas Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/10/04 10:27

147.72 円

163.39 円

196.69 円

ページTOPに戻る